Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $176.42 USD
Change Today -6.81 / -3.72%
Volume 565.5K
JAZZ On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (JAZZ) Snapshot

Open
$183.12
Previous Close
$183.23
Day High
$183.12
Day Low
$176.19
52 Week High
04/27/15 - $191.01
52 Week Low
05/9/14 - $120.38
Market Cap
10.7B
Average Volume 10 Days
453.0K
EPS TTM
$3.88
Shares Outstanding
60.7M
EX-Date
--
P/E TM
45.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (JAZZ)

jazz pharmaceuticals plc (JAZZ) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (JAZZ) Details

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.

870 Employees
Last Reported Date: 02/24/15

jazz pharmaceuticals plc (JAZZ) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $830.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $402.9K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $493.5K
Executive Vice President and General Counsel
Total Annual Compensation: $483.5K
Senior Vice President of U.S. Commercial
Total Annual Compensation: $296.2K
Compensation as of Fiscal Year 2014.

jazz pharmaceuticals plc (JAZZ) Key Developments

Jazz Pharmaceuticals and Gentium Announce European Launch of Severe VOD Drug

Jazz Pharmaceuticals plc and Gentium S.p.A. have announced the European commercial launch of Defitelio, a licensed product for the treatment of severe hepatic veno-occlusive disease, or severe VOD, or sVOD, in patients over one month of age undergoing haematopoietic stem cell transplantation, or HSCT, therapy. The companies have launched Defitelio in Germany and Austria and expect to continue the launch in 27 additional European countries on a rolling basis during 2014 and 2015. The efficacy of Defitelio to treat sVOD in HSCT patients is supported by data from a pivotal, multi-centre Phase III trial that evaluated Defitelio for the treatment of sVOD compared with a historical control group of patients who had received standard supportive care. In this trial, Defitelio was shown to provide a significant increase in survival rates for patients with sVOD in HSCT. The results demonstrated a 52% increase in survival at 100 days after transplantation for patients treated with Defitelio compared to patients in the historical control group (38.2% in the Defitelio group vs. 25.0% in the historical control group; p=0.0341). In the clinical trial, 23.5% of patients treated with Defitelio achieved complete response at 100 days after transplantation versus 9.4% of patients in the historical control group (p=0.013). The efficacy data from this pivotal trial are supported with data from a Phase II dose-finding study, as well as data from the International Compassionate Use Programme and an interim analysis (subset of patients with sVOD) of an ongoing, open-label treatment investigational new drug (IND) study being conducted in the US (US). Additionally, data derived from an independent registry in the US supported the European approval of Defitelio for use in patients with sVOD. Treatment with Defitelio has generally been well tolerated in all age groups. In the Phase III pivotal trial, the overall incidence of adverse events was similar in the Defitelio treatment group and in the control group. The most frequent adverse events observed during pre-marketing use were haemorrhage, hypotension and coagulopathy.

Jazz Pharmaceuticals Public Limited Company Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

Jazz Pharmaceuticals Public Limited Company Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.

Jazz Pharmaceuticals plc Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year 2015; Reports Impairment Charges for the Fourth Quarter Ended December 31, 2014

Jazz Pharmaceuticals plc announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues were $328,142,000 against $235,774,000 a year ago. Income from operations was $129,919,000 against $94,499,000 a year ago. Income before income tax provision was $115,244,000 against $87,357,000 a year ago. Net income was $81,611,000 against $55,293,000 a year ago. Net income attributable to the company was $81,612,000 or $1.30 diluted earnings per share against $55,293,000 or $0.90 diluted earnings per share a year ago. Non GAAP adjusted net income attributable to company was $153,110,000 against $106,126,000 a year ago. Non - GAAP adjusted net income attributable to company per diluted share was $2.44 against $1.72 a year ago. Non GAAP income before income tax provision was $188,871,000 against $129,739,000 a year ago. For the year, the company reported total revenues were $1,172,875,000 against $872,423,000 a year ago. Income from operations was $195,587,000 against $340,312,000 a year ago. Income before income tax provision was $151,557,000 against $307,950,000 a year ago. Net income was $57,326,000 against $216,312,000 a year ago. Net income attributable to the company was $58,387,000 or $0.93 diluted earnings per share against $216,312,000 or $3.51 diluted earnings per share a year ago. Non – GAAP adjusted net income attributable to company was $527,554,000 against $388,257,000 a year ago. Non - GAAP adjusted net income attributable to company per diluted share was $8.43 against $6.31 a year ago. Total revenues for the fourth quarter of 2014 were $328.1 million, an increase of 39% over total revenues of $235.8 million for the fourth quarter of 2013. The increases in total revenues were driven primarily by net product sales of xyrem (sodium oxybate) oral solution, erwinaze/erwinase (asparaginase erwinia chrysanthemi) and defitelio (defibrotide). Total revenues include net product sales, royalties and contract revenues. Non GAAP income before income tax provision was $651,850,000 against $474,642,000 a year ago. For the year 2015, the company expects GAAP net income attributable to company in the range of $323 million to $356 million, Non-GAAP adjusted net income attributable to company in the range of $595 million to $614 million, GAAP net income attributable to company per diluted share in the range of $5.17 to $5.70, Non - GAAP net income attributable to company per diluted share in the range of $9.45 to $9.75, revenue between $1,310 million to $1,370 million; total net product sales between $1,303 million to $1,363 million; and adjusted gross margin between 92% to 93%, adjusted R&D expenses of $95 to $105 million, adjusted interest expense of $40 million For the fourth quarter of 2014, the company reported impairment charges of $6,559,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JAZZ:US $176.42 USD -6.81

JAZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $40.00 USD -2.21
Alkermes PLC $55.74 USD -1.87
BioMarin Pharmaceutical Inc $113.92 USD -2.40
Incyte Corp $97.50 USD -3.50
Sagent Pharmaceuticals Inc $23.68 USD +0.11
View Industry Companies
 

Industry Analysis

JAZZ

Industry Average

Valuation JAZZ Industry Range
Price/Earnings 100.0x
Price/Sales 9.5x
Price/Book 8.1x
Price/Cash Flow 60.1x
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.